Craft

STADA

Stock Price

€82.4

2017-10-30

Market Capitalization

€5.1 B

2017-10-30

Revenue

€3 B

FY, 2020

STADA Summary

Company Summary

Overview
STADA Arzneimittel is a company engaged in the healthcare and pharmaceuticals business. It operates in two segments: Generics and Branded Products. The Generics segment provides generic active ingredients, including Tilidin Naloxon for pain, Atorvastatin for elevated cholesterol levels, etc. The Branded Products segment offers Bortezomib STADA for cancer, APO-Go for Parkinson's disease. The company caters to doctors, pharmacists, patients, health insurance organizations, and other companies.
Type
Public
Status
Active
Founded
1895
HQ
Bad Vilbel, DE | view all locations
Website
https://www.stada.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Peter Goldschmidt

    Peter Goldschmidt, Chairman of the Executive Board/CEO

  • Miguel Pagan Fernandez

    Miguel Pagan Fernandez, Chief Technical Officer

  • Wolfgang Ollig

    Wolfgang Ollig, Chief Financial Officer, CFO

  • Christoph Dengler

    Christoph Dengler, Executive Vice President Global Legal

Operating MetricsView all

Approval Applications Filled to Date

1.2K

FY, 2019

New Products Introduced

729

FY, 2019

Countries (Sales Offices)

120

Nov, 2020

LocationsView all

12 locations detected

  • Bad Vilbel, HE HQ

    Germany

    Stadastraße 2-18

  • Beijing, Beijing Shi

    China

    15 Yunteng Rd, Miyun Qu

  • Hangzhou Shi, Zhejiang Sheng

    China

    887 Jiangcheng Rd, Cheng Zhan Shang Quan, Shangcheng Qu

  • Shanghai, Shanghai Shi

    China

    1808, 1 Dapu Rd, Da Pu Qiao, Huangpu Qu

  • Bad Vilbel, HE

    Germany

    Theodor-Heuss-Straße 52

  • Budapest

    Hungary

and 6 others

STADA Financials

Summary Financials

Revenue (FY, 2020)
€3.0B
Gross profit (FY, 2020)
€1.7B
Net income (FY, 2020)
€181.9M
Cash (FY, 2020)
€266.0M
EBIT (FY, 2020)
€402.0M
Enterprise value
$7.7B

Footer menu